1. Background
2. Methods
| Province | Age Categories, mo | No. of E. coli (No. of EAEC, rateb) | |||||
|---|---|---|---|---|---|---|---|
| 0 - 11 | 12 - 23 | 24 - 35 | 36 - 47 | 48 - 59 | 60 - 79 | ||
| Tehran | 4 (2) | 2 (0) | 3 (1) | 0 (0) | 2 (1) | 1 (0) | 12 (4, 23.5) |
| Alborz | 2 (1) | 1 (0) | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 4 (2, 11.8) |
| Yazd | 0 (0) | 6 (0) | 1 (0) | 4 (2) | 1 (1) | 0 (0) | 12 (3, 17.7) |
| Hamadan | 1 (1) | 1 (0) | 1 (0) | 0 (0) | 1 (0) | 1 (1) | 5 (2, 11.8) |
| Kurdistan | 2 (1) | 1 (0) | 1 (0) | 1 (0) | 0 (0) | 0 (0) | 5 (1, 5.8) |
| Mazandaran | 0 (0) | 1 (1) | 3 (1) | 0 (0) | 1 (0) | 0 (0) | 5 (2, 11.8) |
| Semnan | 0 (0) | 0 (0) | 2 (1) | 0 (0) | 1 (1) | 0 (0) | 3 (2, 11.8) |
| Zanjan | 2 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (1, 5.8) |
| Hormozgan | 0 (0) | 1 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0) |
| Qazvin | 0 (0) | 0 (0) | 1 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0) |
| No. of E. coli (No. of EAEC, rateb) | 11 (5, 29.3) | 13 (2, 11.8) | 12 (3, 17.7) | 6 (3, 17.7) | 6 (3, 17.7) | 2 (1, 5.8) | 50 (17, 100%) |
aIn each box the number of E. coli strains is indicated in the 1st row and the number of strains identified as EAEC is indicated in bold in 2nd row.
bThe rate of EAEC in each category in all the EAEC cases (17 strains) is indicated.
2.1. Polymerase Chain Reaction to Detect Enteroaggregative E. coli Virulence Genes
2.2. Antimicrobial Susceptibility Testing
2.3. Extended Spectrum Beta-Lactamase Production (ESBL) Detection
3. Results
| Pathogens and Province | Antibiotics | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AMP | CTX | CAZ | CRO | MRP | SXT | NAL | GM | CIP | ESBL | |
| EAEC1, T | R | S | S | S | S | R | R | S | S | Neg |
| EAEC2, T | S | S | S | S | S | S | R | S | S | Neg |
| EAEC3, M | R | R | R | R | S | R | R | S | R | Pos |
| EAEC4, H | R | R | R | R | S | R | S | S | S | Pos |
| EAEC5, A | R | R | S | R | S | R | R | S | R | Pos |
| EAEC6, K | S | S | S | S | S | S | S | S | S | Neg |
| EAEC7, Y | S | S | S | S | S | S | S | S | S | Neg |
| EAEC8, T | S | S | S | S | S | S | S | S | S | Neg |
| EAEC9, M | S | S | S | S | S | S | S | S | S | Neg |
| EAEC10,Y | S | S | S | S | S | S | S | S | S | Neg |
| EAEC11, S | S | S | S | S | S | S | S | S | S | Neg |
| EAEC12, Z | R | R | S | R | S | R | S | S | S | Pos |
| EAEC13, A | S | S | S | S | S | S | R | S | S | Neg |
| EAEC14, Y | S | S | S | S | S | S | S | S | S | Neg |
| EAEC15, S | R | S | S | S | S | S | R | S | S | Neg |
| EAEC16, H | R | S | S | S | S | R | R | S | S | Neg |
| EAEC17, T | R | S | S | S | S | R | R | S | S | Neg |
| Total resistance (percentageb) | 8 (47.1) | 4 (23.5) | 2 (11.8) | 4 (23.5) | 0 (0) | 7 (41.2) | 8 (47.1) | 0 (0) | 2 (11.8) | 4 (23.5) |
Abbreviations: A, Alborz; AMP, Ampicillin; CAZ, Ceftazidime; CIP, Ciprofloxacin; CRO, Ceftriaxone; CTX, Cefotaxime; EAEC: Enteroaggregative E. coli; ESBL, Extended -Spectrum Beta Lactamase; GM, Gentamycin; H, Hamadan; K, Kurdistan; M, Mazandaran; MRP, Meropenem; NAL, Nalidixic Acid; S, Semnan; SXT, Trimethoprim Sulfametaxazole; T, Tehran; Y, Yazd; Z, Zanjan.
aThe pattern of antibiotic susceptibility and ability of ESBL producing beta lactamase of EAEC isolates are shown in this Table.
bPercentage: percentage of resistant cases in total number of EAEC isolates.